Related Experiment Video

Updated: Sep 28, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

[Primary progressive multiple sclerosis]

L Brieva1, J Río, X Montalbán

  • 1Unidad de Neuroinmulogía Clínica. Hospital de la Vall d'Hebron, Barcelona, España.

Revista De Neurologia
|December 24, 2002
PubMed

Insights

Mainly progressive multiple sclerosis (MPMS), a rare form of multiple sclerosis, presents unique clinical, immunological, and radiological features. This review covers its characteristics, diagnostic criteria, and limited therapeutic options.

Area of Science:

  • Neurology
  • Immunology
  • Radiology

Background:

  • Mainly progressive multiple sclerosis (MPMS) affects 10-20% of multiple sclerosis patients.
  • MPMS exhibits distinct clinical characteristics differentiating it from other disease progression forms.

Purpose of the Study:

  • To review the immunological and radiological behavior of MPMS.
  • To discuss current disease classifications and diagnostic criteria.
  • To comment on therapeutic options and future prospects for MPMS patients.

Main Methods:

  • Literature review focusing on immunological and radiological aspects.
  • Analysis of recent classifications and diagnostic criteria.
  • Evaluation of current therapeutic strategies.

Main Results:

  • MPMS has specific immunological and radiological profiles.
  • Evolving classifications and diagnostic criteria are presented.
  • Limited therapeutic options currently exist for MPMS.

Conclusions:

  • Understanding MPMS's unique characteristics is crucial for diagnosis and management.
  • Further research is needed to identify effective treatments for MPMS.
  • Future prospects for MPMS patients remain challenging but evolving.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...